WO2002094248A3 - Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schefelhatigen aminosäuren in entnommenem blut - Google Patents

Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schefelhatigen aminosäuren in entnommenem blut Download PDF

Info

Publication number
WO2002094248A3
WO2002094248A3 PCT/EP2002/005368 EP0205368W WO02094248A3 WO 2002094248 A3 WO2002094248 A3 WO 2002094248A3 EP 0205368 W EP0205368 W EP 0205368W WO 02094248 A3 WO02094248 A3 WO 02094248A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acids
acids containing
containing sulphur
inhibiting
composition
Prior art date
Application number
PCT/EP2002/005368
Other languages
English (en)
French (fr)
Other versions
WO2002094248A2 (de
Inventor
Heinrich Wieland
Emanuel Bisse
Original Assignee
Heinrich Wieland
Emanuel Bisse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heinrich Wieland, Emanuel Bisse filed Critical Heinrich Wieland
Priority to JP2002590967A priority Critical patent/JP2004534766A/ja
Priority to US10/478,570 priority patent/US7306950B2/en
Priority to DE50212763T priority patent/DE50212763D1/de
Priority to AU2002325825A priority patent/AU2002325825A1/en
Priority to EP02760166A priority patent/EP1392375B1/de
Priority to CA2447663A priority patent/CA2447663C/en
Publication of WO2002094248A2 publication Critical patent/WO2002094248A2/de
Publication of WO2002094248A3 publication Critical patent/WO2002094248A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/2525—Stabilizing or preserving

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung bezieht sich auf eine Zusammensetzung zur Stabilisierung von schwefelhaltigen Aminosäuren und/oder zur Hemmung der fortlaufenden Bildung von schwefelhaltigen Aminosäuren in entnommenem Blut, auf die Verwendung geeigneter Substanzen und Zusammensetzungen hierfür sowie gegebenenfalls zur Bestimmung von schwefelhaltigen Aminosäuren im Blut, auf ein Verfahren zu diesen Zwecken sowie auf eine für dieses Verfahren geeigneter Weise eingesetzte Blutsammelvorrichtung.
PCT/EP2002/005368 2001-05-21 2002-05-15 Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schefelhatigen aminosäuren in entnommenem blut WO2002094248A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002590967A JP2004534766A (ja) 2001-05-21 2002-05-15 含硫アミノ酸の安定化のための物質の組成物および使用
US10/478,570 US7306950B2 (en) 2001-05-21 2002-05-15 Composition and use of substances for stabilising amino acids containing sulphur
DE50212763T DE50212763D1 (de) 2001-05-21 2002-05-15 Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schwefelhatigen aminosäuren in entnommenem blut
AU2002325825A AU2002325825A1 (en) 2001-05-21 2002-05-15 Composition and use of substances for stabilising amino acids containing sulphur and/or for inhibiting the continuous formation of amino acids containing sulphur in a blood sample
EP02760166A EP1392375B1 (de) 2001-05-21 2002-05-15 Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schwefelhatigen aminosäuren in entnommenem blut
CA2447663A CA2447663C (en) 2001-05-21 2002-05-15 Composition and use of substances for the stabilization of sulphur-containing amino acids

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10124820A DE10124820A1 (de) 2001-05-21 2001-05-21 Zusammensetzung und Verwendung von Substanzen zur Stabilisierung von schwefelhaltigen Aminosäuren im Blut
DE10124820.2 2001-05-21

Publications (2)

Publication Number Publication Date
WO2002094248A2 WO2002094248A2 (de) 2002-11-28
WO2002094248A3 true WO2002094248A3 (de) 2003-10-23

Family

ID=7685648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/005368 WO2002094248A2 (de) 2001-05-21 2002-05-15 Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schefelhatigen aminosäuren in entnommenem blut

Country Status (8)

Country Link
US (1) US7306950B2 (de)
EP (1) EP1392375B1 (de)
JP (1) JP2004534766A (de)
AT (1) ATE407713T1 (de)
AU (1) AU2002325825A1 (de)
CA (1) CA2447663C (de)
DE (2) DE10124820A1 (de)
WO (1) WO2002094248A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027935A1 (en) * 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651414A (en) * 1979-10-02 1981-05-09 Toyo Jozo Co Ltd Antibiotic substance neplanocin preparation
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
WO2000013691A2 (en) * 1998-09-03 2000-03-16 Kerckhoff-Klinik Gesellschaft MIT Beschränkter Haftung 3-deazaadenosine prevents atherosclerosis and graft vasculopathy
WO2000078311A1 (en) * 1999-04-20 2000-12-28 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
EP1085083A1 (de) * 1998-06-01 2001-03-21 Chugai Seiyaku Kabushiki Kaisha Medien zur kultivierung von tierischen zellen und verfahren zur herstellung eines proteins durch deren verwendung
WO2001081920A2 (en) * 2000-04-20 2001-11-01 Biolog, Inc. Comparative phenotype analysis for assessment of biologically active compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148888A (en) * 1978-03-13 1979-04-10 The United States Of America As Represented By The Department Of Health, Education And Welfare 3-Deazaadenosine as an inhibitor of adenosylhomocysteine hydrolase with antiviral activity
US4386093A (en) * 1981-09-16 1983-05-31 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services (±)3-Deazaaristeromycin and uses
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
DE19713088C1 (de) * 1997-03-27 1998-11-26 Reiner Dr Probst Verfahren und Blutabnahmegefäß zur Aufbereitung von Blutproben für die Homocystein- und/oder Folatbestimmung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5651414A (en) * 1979-10-02 1981-05-09 Toyo Jozo Co Ltd Antibiotic substance neplanocin preparation
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
EP1085083A1 (de) * 1998-06-01 2001-03-21 Chugai Seiyaku Kabushiki Kaisha Medien zur kultivierung von tierischen zellen und verfahren zur herstellung eines proteins durch deren verwendung
WO2000013691A2 (en) * 1998-09-03 2000-03-16 Kerckhoff-Klinik Gesellschaft MIT Beschränkter Haftung 3-deazaadenosine prevents atherosclerosis and graft vasculopathy
WO2000078311A1 (en) * 1999-04-20 2000-12-28 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2001081920A2 (en) * 2000-04-20 2001-11-01 Biolog, Inc. Comparative phenotype analysis for assessment of biologically active compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AL-KHAFAJI; BOWRON A; DAY A P; SCOTT J; STANSBIE D: "Stabilization of blood homocysteine by 3-deazaadenosine", ANN CLIN BIOCHEM, no. 35, 1998, pages 780 - 782, XP002225386 *
NAUCK M; BISSE E; NAUCK M; WIELAND H: "Pre-Analytical conditions affecting the determination of the plasma homocysteine concentration", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol. 39, no. 8, August 2001 (2001-08-01), pages 675 - 680, XP009002815 *
PATENT ABSTRACTS OF JAPAN *
SASO Y; CONNER E M; TEEGARDEN B R; ET AL: "S-Adenosyl-L-homocysteine Hydrolase Inhibitor mediates immunosuppressive effects in vivo", J. PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 296, no. 1, 2001, pages 106 - 112, XP002225857 *
SIMING LIU ET AL: "RATIONAL APPROACHES TO THE DESIGN OF ANTIVIRAL AGENTS BASED ON S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE AS A MOLECULAR TARGET", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 19, no. 3, 1 September 1992 (1992-09-01), pages 247 - 265, XP000601270, ISSN: 0166-3542 *
WILLEMS H; BOS G; GERRITS W: "Acidic Citrate stabilizes blood samples for assay of total homocystein", CLINICAL CHEMISTRY, vol. 44, 1998, pages 342 - 345, XP002225387 *

Also Published As

Publication number Publication date
CA2447663C (en) 2011-10-11
CA2447663A1 (en) 2002-11-28
ATE407713T1 (de) 2008-09-15
JP2004534766A (ja) 2004-11-18
US7306950B2 (en) 2007-12-11
US20040138169A1 (en) 2004-07-15
DE10124820A1 (de) 2002-12-05
AU2002325825A1 (en) 2002-12-03
DE50212763D1 (de) 2008-10-23
EP1392375B1 (de) 2008-09-10
EP1392375A2 (de) 2004-03-03
WO2002094248A2 (de) 2002-11-28

Similar Documents

Publication Publication Date Title
WO2005052542A3 (en) Method and composition useful for determining fk 506
WO2002072605A3 (en) Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002095396A3 (en) In line test device and methods of use
AU2001288032A1 (en) Method and kit for the transderaml determination of analyte concentration in blood
AU2002346484A1 (en) Method and apparatus for improving the accuracy of alternative site analyte concentration measurements
IL210633A0 (en) Compositions and processes for analyte detection
IL150970A0 (en) Devices for analyte concentration determination and methods of using the same
WO2002083105A3 (en) Composition for enhanced absorption of nsaids
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
MXPA03003682A (es) Metodo para determinar la coagulabilidad y el potencial hemostatico globales.
WO2002041881A3 (de) Repinotan-kit
IL153860A0 (en) Method and apparatus for determining the composition of fluids
DE69911654D1 (de) Verfahren zur verringerung des metallgehalts von erdölströmen
GB2380544B (en) Method and combined visibility and precipitation measuring instrument for determining visibility, amount of precipitation and type of precipitation
WO2003020963A3 (en) Proteins in type 2 diabetes
ATE385314T1 (de) Verfahren zur feststellung wenigstens eines zustandsparameters eines dichtungssystems sowie dichtungssystem
WO2002094248A3 (de) Zusammensetzung und verwendung von substanzen zur stabilisierung von schwefelhaltigen aminosäuren und/oder zur hemmung der fortlaufenden bildung von schefelhatigen aminosäuren in entnommenem blut
WO2005013915A3 (en) Novel indications for transforming growth factor-beta regulators
WO2002100805A3 (en) Colorimetric nanocrystal sensors, methods of making, and use thereof
WO2005037231A3 (en) Methods of detecting and treating facioscapulohumeral muscular dystrophy
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
AU2001294237A1 (en) Method for measuring flow velocity of molten metal and its instrument, and measuring rod used for this
WO2004004455A3 (de) Zusammensetzung und verfahren zur stabilisierung von biomolekülen
WO2000065056A3 (en) NUCLEIC ACIDS ENCODING A mutT DOMAIN-CONTAINING POLYPEPTIDE
AU2001288107A1 (en) Liquid deodorant composition and method for use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002760166

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2447663

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002590967

Country of ref document: JP

Ref document number: 10478570

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002760166

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002760166

Country of ref document: EP